SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE : revenue, balance sheet and financial ratios

SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE is a French company founded 15 years ago, specialized in the sector Activités des sociétés holding. Based in VERSAILLES (78000), this company of category PME shows in 2024 a revenue of 21 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE (SIREN 522943679)
Indicator 2024 2023 2021 2020 2019 2018 2017 2016
Revenue 21 000 € 48 000 € 48 000 € 48 000 € 48 000 € 47 500 € 42 000 € 30 000 €
Net income 3 295 € 18 031 € 47 038 € 67 648 € 87 654 € 62 760 € 63 393 € 47 738 €
EBITDA -3 000 € 8 825 € 4 696 € 5 064 € 5 925 € -433 € -3 718 € 19 450 €
Net margin 15.7% 37.6% 98.0% 140.9% 182.6% 132.1% 150.9% 159.1%

Revenue and income statement

In 2024, SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE achieves revenue of 21 k€. Activity remains stable over the period (CAGR: -4.4%). Significant drop of -56% vs 2023. After deducting consumption (0 €), gross margin stands at 21 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -3 k€, representing -14.3% of revenue. Warning negative scissor effect: despite revenue change (-56%), EBITDA varies by -134%, reducing margin by 32.7 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3 k€, i.e. 15.7% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

21 000 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

21 000 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-3 000 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-3 000 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

3 295 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-14.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 99%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 15.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

99.331%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

15.69%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE

Sector positioning

Debt ratio
0.0 2024
2021
2023
2024
Q1: 0.01
Med: 8.77
Q3: 62.6
Excellent -6 pts over 3 years

In 2024, the debt ratio of SFIP SOC FINANC INVESTIS... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
99.33% 2024
2021
2023
2024
Q1: 15.71%
Med: 62.26%
Q3: 91.3%
Excellent

In 2024, the financial autonomy of SFIP SOC FINANC INVESTIS... (99.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2021
2023
2024
Q1: 0.0 years
Med: 0.09 years
Q3: 3.07 years
Excellent -26 pts over 3 years

In 2024, the repayment capacity of SFIP SOC FINANC INVESTIS... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 369.26. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

369.26

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE

Sector positioning

Liquidity ratio
369.26 2024
2021
2023
2024
Q1: 138.65
Med: 681.09
Q3: 3914.52
Average +11 pts over 3 years

In 2024, the liquidity ratio of SFIP SOC FINANC INVESTIS... (369.26) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
0.0x 2024
2021
2023
2024
Q1: -74.77x
Med: 0.0x
Q3: 0.0x
Good -25 pts over 3 years

In 2024, the interest coverage of SFIP SOC FINANC INVESTIS... (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 133 days. Excellent situation: suppliers finance 133 days of the operating cycle (retail model). Overall, WCR represents 172 days of revenue, i.e. 10 k€ to permanently finance. Over 2016-2024, WCR increased by +106%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

10 045 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

133 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

172 j

WCR and payment terms evolution
SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE

Positioning of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Based on 54 transactions of similar company sales in 2024, the value of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE is estimated at 9 342 € (range 5 842€ - 18 662€). The price/revenue ratio is 0.59x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
54 tx
5k€ 9k€ 18k€
9 342 € Range: 5 842€ - 18 662€
NAF 5 année 2024

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
21 000 € × 0.59x
Estimation 12 364 €
7 692€ - 14 699€
Net Income Multiple 20%
3 295 € × 1.5x
Estimation 4 811 €
3 068€ - 24 609€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE

What is the revenue of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE ?

The revenue of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE in 2024 is 21 k€.

Is SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE profitable?

Yes, SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE generated a net profit of 3 k€ in 2024.

Where is the headquarters of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE ?

The headquarters of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE is located in VERSAILLES (78000), in the department Yvelines.

Where to find the tax return of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE ?

The tax return of SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE operate?

SFIP SOC FINANC INVESTISSEMENT PHARMACEUTIQUE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.